Abstracts Special issue on Animal Physiology 2013, vol. 2, Abstracts special issue
Marcela Tavačová, Milan Luknár, Iveta Šimková, Peter Lesný, Eva Goncalvesová
Biotechnology of Biotechnology
Portopulmonary hypertension (POPH) is associated with a poor prognosis in comparison to some other types of pulmonary arterial hypertension (PAH). Due to various causes of portal hypertension, the subgroup of POPH can be heterogeneous and PAH is considered to be related more closely to portal hypertension than to an intrinsic hepatic disorder.
We report a retrospective series of 4 consecutive patients with severe POPH due to pre-hepatic portal hypertension and no signs of liver function impairment. All of them were non-responders to acute vasoreactivity testing and were treated with specific treatment.
Patient 1 (male) was diagnosed with PAH at the age of 4. At the age of 31, his status deteriorated, dysphonia and abdominal dyscomfort appeared and his PAH was linked to newly diagnosed portal vein atresia. Sildenafil treatment was initiated. After 6 years of treatment, the patient is asymptomatic. Patient 2 (female) was diagnosed with PAH associated with portal vein agenesis at the age of 27. At the age of 30, symptoms worsened and peripheral edema developed. Ambrisentan treatment was initiated. After 4 years of specific treatment, the patient is asymptomatic. Patient 3 (male) was diagnosed with PAH associated with post-traumatic portal vein thrombosis at the age of 49 and bosentan was introduced. After 6 yrs of treatment, the patient’s status remains stable, he is mildly symptomatic. Patient 4 (female) was diagnosed with PAH associated with spontaneous portal vein thrombosis due to hypercoagulable state at the age of 48. Sildenafil treatment was started and her status improved. 2 yrs after treatment initiation, her condition deteriorated (WHO FC III, 6-min walking distance 200 m), and ambrisentan was added. After another 2 yrs of combination treatment, her status remains improved in WHO class II. In all cases, no major adverse effects of specific treatment have been reported. Main patient characteristics are summarized in Table 1.
Specific treatment in this small case series of pts with POPH due isolated portal vein disease uniformly resulted in an improvement of clinical status, markers of prognosis, and long term survival. This supports the opinion that POPH is a heterogeneous clinical condition with POPH due to pre-hepatic portal hypertension possibly being a distinct entity. Specific treatment including ERA antagonist seems to be warranted and these patients should not be excluded from randomized clinical trials.